---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-003181"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:13:48.849345+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics closes $5.0M public offering of common stock and warrants

## Summary
- Gross proceeds of $5.0M from offering of 1.62M shares (or pre-funded warrants) plus Series A/B warrants at $2.82 exercise price.
- Net proceeds approx. $4.2M; H.C. Wainwright acted as placement agent with 7.0% cash fee.
- Existing warrants for 235,849 shares amended: exercise price lowered from $21.20 to $2.82, expiry extended to 5 years.
- Offering closed March 20, 2023; 60-day lock-up on further equity issuance and one-year variable-rate transaction ban.

## SEC filing metadata
- accession: 0001654954-23-003181
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/0001654954-23-003181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-003181
- JSON: https://secwatch.observer/filing/0001654954-23-003181.json
- Plain text: https://secwatch.observer/filing/0001654954-23-003181.txt

## Key facts
- Material Agreements
  Dermata Therapeutics, Inc. entered into Purchase Agreement with an investor valued at approximately $4.2 million (effective 2023-03-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor
  - Value: approximately $4.2 million
  - Effective: 2023-03-16
  source text: On March 16, 2023, Dermata Therapeutics, Inc. (the " Company ") entered into a securities purchase agreement with an investor (the " Purchase Agreement ") pursuant to which the Company agreed to sell, in a best efforts public offering (the " Offering ") priced at the market under Nasdaq rules, an aggregate of (i) 85,000 shares (the " Shares ") of common stock, par value $0.0001 per share (the " Common Stock "), of the Company, (ii) pre-funded warrants (the " Pre-Funded Warrants ") to purchase up to an aggregate of 1,533,123 shares of Common Stock (the " Pre-Funded Warrant Shares "), (iii) Series A warrants (the " Series A Common Warrants ") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the " Series A Warrant Shares "), and (iv) Series B warrants (the " Series B Common Warrants " and collectively with the Series A Warrants, the " Warrants ") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the " Series B Warrant Shares " and together with the Ser
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/0001654954-23-003181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.